Drug intelligence / Profile preview

VEGI-192

Development stage: Preclinical
Lead developer: Matrix Biomed
Modality: Small Molecules
Administration: Intraperitoneal, Intravenous, Subcutaneous

Overview

VEGI-192 is a preclinical-stage small molecule therapeutic developed by Matrix Biomed for the treatment of solid tumors and macular degeneration. The compound is designed to act as an inducer of Vascular Endothelial Growth Inhibitor (VEGI), also known as TNFSF15. VEGI is an endogenous cytokine and a member of the tumor necrosis factor (TNF) family that naturally inhibits angiogenesis and endothelial cell proliferation. By upregulating the expression of VEGI, VEGI-192 aims to suppress pathological neovascularization, which is a key driver of tumor progression and vision loss in conditions such as wet age-related macular degeneration (AMD).

Targets

DR6 (Tumor necrosis factor receptor superfamily member 21)DR3 (Tumor necrosis factor receptor superfamily member 25)TL1A (TNF-like cytokine 1A)

Beyond the preview

Go deeper on VEGI-192.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VEGI-192.